Austar Lifesciences Limited provided consolidated earnings guidance for the year ended 31 December 2022. It is expected that a profit attributable to the owners of the Company of not less than RMB 50 million will be recorded for the year ended 31 December 2022, as compared with that of approximately RMB 277.3 million for the year ended 31 December 2021.